Use of PELC/CpG Adjuvant for Intranasal Immunization with Recombinant Hemagglutinin to Develop H7N9 Mucosal Vaccine

Human infections with H7N9 avian influenza A virus can result in severe diseases with high mortality. Developing an effective vaccine is urgently needed to prevent its pandemic potential. Vaccine delivery routes via mucosal surfaces are known to elicit mucosal immune responses such as secretory IgA...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ting-Hsuan, Chen, Chung-Chu, Huang, Ming-Hsi, Huang, Chung-Hsiung, Jan, Jia-Tsrong, Wu, Suh-Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349964/
https://www.ncbi.nlm.nih.gov/pubmed/32455704
http://dx.doi.org/10.3390/vaccines8020240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349964/
https://www.ncbi.nlm.nih.gov/pubmed/32455704
http://dx.doi.org/10.3390/vaccines8020240

Ejemplares similares